Caxton Associates LLP Sells 103,802 Shares of Ginkgo Bioworks Holdings, Inc. $DNA

Caxton Associates LLP lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 60.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,778 shares of the company’s stock after selling 103,802 shares during the quarter. Caxton Associates LLP owned about 0.11% of Ginkgo Bioworks worth $422,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Ginkgo Bioworks by 3.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,727 shares of the company’s stock valued at $267,000 after purchasing an additional 1,122 shares during the period. Shay Capital LLC grew its position in Ginkgo Bioworks by 6.2% during the 2nd quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock worth $218,000 after acquiring an additional 1,124 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Ginkgo Bioworks by 3.5% in the fourth quarter. Deutsche Bank AG now owns 35,689 shares of the company’s stock valued at $297,000 after buying an additional 1,207 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Ginkgo Bioworks by 2.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 94,873 shares of the company’s stock worth $789,000 after acquiring an additional 1,869 shares during the last quarter. Finally, Quarry LP acquired a new position in Ginkgo Bioworks during the 3rd quarter worth $29,000. Institutional investors own 78.63% of the company’s stock.

Wall Street Analyst Weigh In

DNA has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Friday, July 17th. Wall Street Zen lowered shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $8.50.

Ginkgo Bioworks Trading Up 1.4%

NYSE DNA opened at $7.46 on Tuesday. The company has a market cap of $487.42 million, a price-to-earnings ratio of -1.39 and a beta of 1.77. The company has a 50 day moving average of $8.79 and a 200-day moving average of $8.39. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.37 and a 1-year high of $17.58.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.18). The firm had revenue of $19.00 million for the quarter, compared to analyst estimates of $42.93 million. Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.